KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Free Cash Flow: 2013-2025

Historic Free Cash Flow for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to -$72.0 million.

  • Xenon Pharmaceuticals' Free Cash Flow fell 43.33% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$253.3 million, marking a year-over-year decrease of 53.72%. This contributed to the annual value of -$184.5 million for FY2024, which is 17.70% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Free Cash Flow is -$72.0 million, which was down 11.87% from -$64.4 million recorded in Q2 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Free Cash Flow peaked at -$14.0 million during Q2 2021, and registered a low of -$72.0 million during Q3 2025.
  • Over the past 3 years, Xenon Pharmaceuticals' median Free Cash Flow value was -$49.3 million (recorded in 2023), while the average stood at -$49.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first grew by 11.71% in 2022, then plummeted by 103.04% in 2023.
  • Xenon Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$21.2 million in 2021, then plummeted by 74.72% to -$37.1 million in 2022, then rose by 4.32% to -$35.5 million in 2023, then plummeted by 55.49% to -$55.2 million in 2024, then crashed by 43.33% to -$72.0 million in 2025.
  • Its last three reported values are -$72.0 million in Q3 2025, -$64.4 million for Q2 2025, and -$61.7 million during Q1 2025.